[Summary] 29.7% of the Population Have Received First Dose of Vaccine... 7,723 Adverse Reactions Reported Over Three Days

[Asia Economy Reporter Seulgina Jo] The number of people receiving the first dose of the COVID-19 vaccine in South Korea increased by about 46,000 on the 25th. As of midnight that day, the total cumulative number of first-dose vaccinations in the country reached 15,263,225, accounting for 29.7% of the total population. As vaccination expands, the number of reported adverse reactions after vaccination is also steadily increasing.

◆ Total 15,263,225 First Doses, 29.7% of Population... 9% Fully Vaccinated

According to the COVID-19 Vaccination Response Promotion Team (Promotion Team) on the 26th, 46,333 new first-dose vaccinations were administered the previous day. The number of new first-dose vaccinations by vaccine type was 34,349 for Pfizer, 8,946 for Moderna, 2,620 for AstraZeneca (AZ), and 418 for Janssen.

So far, the cumulative number of first-dose vaccinations is 15,263,225. By vaccine type, the cumulative first-dose vaccinations are 10,390,641 for AstraZeneca, 3,729,499 for Pfizer, 1,126,366 for Janssen, and 16,719 for Moderna. Among these, the Janssen vaccine is completed with only the first dose and is included in both first and second dose counts.

The number of people who have completed vaccination increased by 96,129 to 4,618,918, accounting for 9.0% of the total population. The number of fully vaccinated people by vaccine type is 2,592,211 for Pfizer, 900,341 for AstraZeneca, and 1,126,366 for Janssen.

Among AstraZeneca vaccination targets (12,521,630 people), 83.0% have received the first dose. The vaccination rate up to the second dose is 7.2%. For Pfizer, among the total target population (4,424,024 people), 84.3% have received the first dose and 58.6% have completed the second dose. The Janssen vaccine, which requires only one dose, has been administered to 96.4% of the priority vaccination group (1,168,340 people).

On the previous day, a total of 1,359 people received leftover vaccines through the standby list and mobile application (app).

As of midnight that day, 1,775,700 doses of vaccines remain in South Korea. The remaining doses by vaccine type are 1,316,400 for Pfizer, 357,300 for AstraZeneca, 95,900 for Moderna, and 6,100 for Janssen.

◆ 7,723 Reports of Adverse Reactions in Three Days... 24 Additional Deaths

The number of reported adverse reactions after vaccination is also increasing.

From the 23rd to the 25th, 7,723 new cases suspected of adverse reactions after vaccination were reported to health authorities. There were 2,829 reports on the 23rd, 2,517 on the 24th, and 2,377 on the 25th. By vaccine type, there were 5,688 reports for AstraZeneca, 1,137 for Pfizer, 880 for Janssen, and 18 for Moderna.

There were 24 additional death reports. Twelve people each had received AstraZeneca and Pfizer vaccines. Currently, health authorities are investigating the causal relationship between the deaths and the vaccines.

All deceased reporters were in their 60s to 90s. The time from vaccination to death varied from the day of vaccination to 56 days later. An 80-year-old woman who received the Pfizer vaccine died on the day of vaccination, the 24th, and an 80-year-old woman residing in a vulnerable facility who received the AstraZeneca vaccine on April 19 died on the 14th of this month, 56 days later. Among the deceased, 10 had underlying conditions. One had no underlying conditions. The remaining 13 are under investigation for underlying conditions.

Since the start of vaccination in South Korea on February 26, a total of 83,832 suspected adverse reaction reports have been accumulated.

There were 8 new reports suspected of anaphylaxis, a severe systemic allergic reaction. Among these, 6 cases were related to the Pfizer vaccine. AstraZeneca and Janssen each had one case.

There were 331 new reports of major adverse reactions, including 'special interest adverse reactions,' ICU admissions, life-threatening conditions, permanent disabilities, and sequelae. These included 241 for AstraZeneca, 57 for Pfizer, and 33 for Janssen.

The remaining 7,360 cases were confirmed as general adverse reactions such as pain and swelling at the injection site, fever, and headache.

This content was produced with the assistance of AI translation services.